IMV (TSE:IMV) Stock Rating Reaffirmed by HC Wainwright

IMV (TSE:IMV – Get Rating)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, TipRanks reports. They presently have a C$13.00 target price on the stock.

Separately, Echelon Wealth Partners restated a “buy” rating on shares of IMV in a report on Friday, May 13th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of C$5.31.

Shares of TSE:IMV opened at C$0.92 on Wednesday. IMV has a 12 month low of C$0.84 and a 12 month high of C$3.01. The company has a quick ratio of 3.27, a current ratio of 3.85 and a debt-to-equity ratio of 170.58. The company’s fifty day simple moving average is C$1.28 and its 200 day simple moving average is C$1.52. The firm has a market cap of C$75.69 million and a price-to-earnings ratio of -1.38.

About IMV (Get Rating)

IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.

Read More